Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Dec 06, 2016
Results of Meeting
Nov 25, 2016
Investor presentation, 25 November 2016
Nov 14, 2016
Notice of special meeting of shareholders
Nov 14, 2016
Neuren completes enrolment in Rett syndrome Phase 2 trial
Oct 31, 2016
Appendix 4C - quarterly
Oct 28, 2016
Neuren receives $0.9m from exercise of last expiring options
Oct 28, 2016
Appendix 3B
Aug 31, 2016
Change of Director's Interest Notice
Aug 31, 2016
Appendix 3B
Aug 30, 2016
Half Yearly Report and Accounts
1
2
3
4
Next
